Rockwell Medical (RMTI) vs SCYNEXIS (SCYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rockwell Medical (RMTI) has outperformed SCYNEXIS (SCYX) over the past year, losing 34.8% versus a loss of 35.6%. Over five years, RMTI leads with a -88.0% price change compared with -90.8% for SCYX. SCYNEXIS is the larger company by market cap ($40.6 million vs $31.8 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RMTI | SCYX |
|---|---|---|
| Share price | $7.89 | $4.08 |
| Market cap | $31.80M | $40.59M |
| 1-day change | -1.62% | -3.32% |
| YTD return | -4.94% | -19.30% |
| 1-year return | -34.79% | -35.61% |
| 5-year return | -88.05% | -90.84% |
| Forward P/E | 112.71 | — |
| EPS (TTM) | $-1.31 | $-0.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.90 | $9.12 |
| 52-week low | $4.89 | $3.53 |
| Distance from 52-week high | -38.84% | -55.26% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +153.49% | +790.44% |
| Average volume | 26.44K | 281.75K |
| Shares outstanding | 4.03M | 9.95M |
| Employees | 157 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Rockwell Medical
RMTI stock →Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers.
Health Care · Biotechnology: Pharmaceutical Preparations · 157 employees
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
RMTI vs SCYX FAQ
Which is bigger, Rockwell Medical or SCYNEXIS?
SCYNEXIS (SCYX) is larger, with a market capitalization of $40.59M compared with $31.80M for Rockwell Medical (RMTI).
Which stock has performed better over the past year, RMTI or SCYX?
RMTI returned -34.79% over the past 12 months, compared with -35.61% for SCYX (price return, excluding dividends). Past performance does not predict future results.
Are Rockwell Medical and SCYNEXIS in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.